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ABSTRACT 
 
Prediction of psychosis in subjects at clinical high risk (CHR) has become a mainstream focus 
of clinical and research interest worldwide. When using CHR instruments for clinical 
purposes, the predicted outcome is but only a probability; and, consequently, any therapeutic 
action following the assessment is based on probabilistic prognostic reasoning. Yet, 
probabilistic reasoning makes considerably demands on the clinicians. We provide here a 
scholarly practical guide summarizing the key concepts to support clinicians with 
probabilistic prognostic reasoning in the CHR state. We review risk or cumulative incidence 
of psychosis in, person-time rate of psychosis, Kaplan-Meier estimates of psychosis risk, 
measures of prognostic accuracy, sensitivity and specificity in Receiver Operator 
Characteristic (ROC) curves, positive and negative predictive values, Bayes’ theorem, 
likelihood ratios, potentials and limits of real-life applications of prognostic probabilistic 
reasoning in the CHR state. Understanding basic measures used for prognostic probabilistic 
reasoning is a prerequisite for successfully implementing the early detection and prevention 
of psychosis in clinical practice. Future refinement of these measures for CHR subjects may 
actually influence risk management, especially as regards initiating or withholding treatment. 
 
 
 
 
 
 
 
 
 
 
1. INTRODUCTION 
Psychoses, in particular schizophrenia, are still one of the most costly and disabling disorders, 
despite their low incidence of 0.032 per 100 person-years (95% CI from 0.025 - 0.041 per 100 
person-years).1. One cause of poor outcome of psychosis is their often long delay in adequate 
treatment initiation which his worsening the long-term general symptomatic outcome, 
positive and negative symptoms, likelihood of remission, social functioning and global 
outcome2. Thus, over the past two decades, increasing efforts have been made to detect and 
treat psychosis early, preferably already during its prodromal phase of often many years in 
order to reduce the untreated psychosis and improve the clinical outcomes3. To an indicated 
prevention of psychosis in persons seeking help already for mental problems, two alternative 
clinical high risk (CHR) approaches to an early detection were developed: (i) the Ultra-High 
Risk (UHR) including Attenuated Psychotic Symptoms (APS), Brief and Limited Intermittent 
Psychotic Symptoms or Brief and Intermittent Psychotic Symptoms (BLIPS/BIPS) as well as 
a combination of Genetic Risk and functional decline (GRD), and (ii) the Basic Symptom 
(BS) approach based on subjective, subtle cognitive and perceptive disturbances that form 
two partly overlapping criteria4. Both approaches (BS and UHR) as well as the instruments 
specifically developed for their assessment have shown the ability to detect a considerably 
increased CHR for psychosis with pooled one- to three-year conversion rates to psychosis 
ranging from 15-29% for UHR5, 6 and from 14-50%7 for BS criteria, and sufficient prognostic 
accuracy of their assessment, in particular in ruling out psychosis risk.8 However, these 
figures are not stable but were shown to vary not only with the follow-up time but also with 
characteristics of the group in which CHR state is assessed, e.g. with age composition9 or 
main referral source.8 Thus, when using these CHR criteria or instruments for clinical 
purposes, the predicted outcome is not a certainty but only a probability; and, consequently, 
any therapeutic action following the assessment is based on probabilistic prognostic reasoning. 
We present here a comprehensive guide summarizing the basic concepts of probabilistic 
prognostic reasoning for psychosis prediction, illustrated by practical examples from the real 
world scenario of high-risk services. We hope this manuscript will be of practical utility for 
clinicians and researchers interested in the early detection of psychosis. 
 
2. PROBABILISTIC PROGNOSTIC REASONING 
2.1 Risk or cumulative incidence of psychosis in CHR samples 
As in any preventive approach, the main aim of an indicated prevention is a reduction in the 
overall morbidity or cumulative incidence of the disease.10 In case of the early detection of 
psychosis, the main outcome is therefore defined by the transition risk to frank psychosis 
from a CHR state11. Thereby, cumulative incidence is usually defined as the probability that a 
particular event, such as occurrence of a particular disease, has occurred within a given 
period.12 Synonyms of cumulative incidence include incidence proportion and risk or 
probability of developing psychosis. It is usually calculated by the following proportion, 
assuming that all CHR patients have been followed-up: 
 Risk  of  psychosis  in  CHR  patients
=   number  of  transitions  to  psychosis  during  a  specified  periodnumber  of  CHR  patients  at  baseline  
 
Such probabilities are commonly defined as the likelihood of an event with values ranging 
from 0 or 0% (no expected occurrence of the event in any case) to 1 or 100% (certain of the 
occurrence of the event in all cases). However, as the risk of psychosis onset in CHR patients 
is the probability that psychosis will occur within a defined period of time and, consequently, 
heavily depends on the observation time, risk of psychosis in CHR patients always has to be 
referred to in terms of a specified follow-up period.  
 
Example A: No consideration of potential dropouts 
One hundred CHR patients were followed-up, first for 1 year and then for another 2, i.e., 
altogether 3 years. At the end of 1 year, 15 patients had developed psychosis. 
à 1-year risk of psychosis = 15 / 100= 0.15 
At the end of 3 years, 14 further patients had developed psychosis, cumulating to altogether 
29 cases with a transition to psychosis within 3 years. 
à 3-year risk of psychosis = (15 + 14) / 100= 0.29 
  
2.3 Person-time or incidence rate of psychosis in CHR  
Other than risk or cumulative incidence of psychosis that assumes that the outcome of all 
CHR patients at the end of the follow-up period is known, the incidence rate or person-time 
rate is a measure that incorporates the true observation time directly into the denominator. 
Thus, it can account for the unfortunately likely persons who dropout during longer 
observation periods. As for the proportion used to compute the cumulative incidence, the 
numerator of the person-time rate is the number of transitions to psychosis during the follow-
up time. However, the denominator is not the baseline number of CHR patients but the total 
of the observation time (commonly given in years) of each CHR patients.  
 
Example B. Consideration of potential dropouts 
Again, 100 CHR patients were followed up annually for 3 years. After 1 year, 15 had 
developed psychosis but 10 were lost to follow-up. After 2 years, 5 had developed 
psychosis and 5 were additionally lost to follow-up. After 3 years, another 9 had developed 
psychosis and 10 were lost to follow-up. To calculate the person-time rate of psychosis, we 
will assume that CHR patients with psychosis onset and those lost to follow-up were 
disease-free for 6 months, and thus contribute 0.5 years to the denominator.  
à Person-time rate of psychosis = (15 + 5 + 9) / (75 + 0.5 × 15 + 0.5 × 10) + (65+ 0.5 × 
5+ 0.5 × 5) + (55+ 0.5 × 9 + 0.5 × 10) = 29 / 222 = 0.13 per persons-years of follow-
up 
 
Thus, the 3-year person time or incidence rate of psychosis with consideration of individual 
observation times (= 3 × 0.13 = 0.39) is considerably higher than the 3-year cumulative 
incidence of Example A (= 0.29). This leads to the question, which measure (person-time rate 
vs cumulative incidence) should followed in clinical practice. Since the cumulative incidence 
ignores patients lost to follow-up, and conservatively assumes that they remained disease-free 
over the years, it might actually underestimate the true probability of psychosis transition in 
CHR samples. Indeed, there is evidence that about 23% of CHR patients who disengage from 
CHR services (drop-outs) will later develop psychosis.13 Thus, in practice, the incidence rate 
relating to person-years should be preferred over the more conservative cumulative incidence 
or risk. 
 
2.4 Kaplan-Meier Estimates of Psychosis Risk in CHR Patients 
An even more accurate time-to-event estimate of risk of psychosis, which also deals with 
incomplete observations is provided by Kaplan-Maier (survival) curves.14 A Kaplan-Maier 
curve is defined as the probability of surviving in a given length of time, thereby considering 
time in many small intervals.15 A previous meta-analysis provided a summary Kaplan-Maier 
estimate of psychosis risk in CHR samples (mainly by UHR criteria), and indicated that most 
transitions occurred within the first two years5. Because of this, it may be clinically relevant 
to know the exact risk of psychosis onset in CHR patients, given psychosis will occur during 
this timeframe (this will apply to most transitions although later transitions are also possible, 
in particular in CHR samples defined by BS criteria).7  
Time to transition, given transition will occur in the first two years, is depicted in Figure 1. 
Such a figure – or rather such a set of figures, considering the impact of type of risk criteria, 
age, referral source and possibly other patient characteristics – might be of clinical interest 
because they might be practically used by CHR clinicians to optimize the timing of their 
prognostic assessments and treatments accordingly (e.g., more frequent CHR re-assessments 
in the first two years to not miss the chance to adapt treatment to possible symptom 
exacerbations16).  
 *** FIGURE 1 ABOUT HERE *** 
 
2.5 Measures of Prognostic Accuracy in CHR samples 
Next to these risk estimates relating predominately to CHR populations, risk estimates that 
rather relate to CHR assessments, i.e., a test’s accuracy measures, are often used in diagnostic 
decision-making.17 These include a range of measures derived from a 2×2 contingency table, 
cross-classifying the binary result of a CHR assessment and the binary result of the follow-up 
gold standard assessment of psychosis (Table 1), that will be discussed in the following.  
 
*** TABLE 1 ABOUT HERE *** 
 
2.6 Sensitivity and Specificity of CHR assessment 
In simple terms, the sensitivity of the CHR assessment is defined as the proportion of patients 
developing psychosis who have a positive CHR assessment result. The specificity of a test is 
the proportion of patients not developing psychosis who have a negative CHR assessment 
result.  
 
Example C: Sensitivity and specificity of a CHR assessment 
150 subjects seeking help at a CHR service undergo CHR assessment. 100 of them are 
deemed at CHR+ and of these 29 will develop psychosis at 3 years (CHR+T). Among the 
50 not considered at risk, i.e. CHR−, 2 will develop psychosis at 3 years (CHR−T) and 48 
will not (CHR−NT). Thus, sensitivity and specificity of the CHR assessment at 3 year 
follow-up are: 
Sensitivity = (CHR+T) × 100 / (CHR+T + CHR−T) = 29 × 100 / (29 + 2) = 93.5% 
Specificity = (CHR−NT) × 100 / (CHR−NT + CHR+NT) = 48 × 100 / (48 + 71) = 40.3% 
 
A perfect assessment would have 100% sensitivity and 100% specificity, yet in the likely 
absence of such perfect values, no clear guidelines to weigh sensitivity against specificity 
exist but only rules-of-thumb.18 For example, Sackett19 (1991) suggested to use the test with 
the highest sensitivity for ‘ruling out’ and that with the highest specificity for ‘ruling in’ the 
disease, irrespective of the number of false-positive or false-negative classifications. In 
contrast, balancing severity of the disorder against risk associated with treatment, NcNeil et 
al.20 (1975) suggested to use highly sensitive tests, even if of little specificity, when the 
disorder is severe but its treatment benign and safe; and highly specific tests, even if of little 
sensitivity, when treatments carry the risk of severe side-effects and long-term consequences. 
Furthermore, clinical utility of sensitivity and specificity is limited by the fact that they 
cannot be directly used to estimate the individual probability of developing psychosis in a 
patient undergoing CHR assessment. Indeed, high sensitivity and specificity do not ensure 
that the test will be clinically useful, nor do low sensitivity and specificity render a test 
useless21. Sensitivity and specificity may also be instable and affected by factors such as 
sampling bias, small samples, bias in test scores, or errors in selection and use of tests21.  
The sensitivity and specificity of CHR assessments have recently been estimated at meta-
analytical level. The prognostic sensitivity for psychosis prediction at 38 months was 96% 
(95%CI: 92 – 98%), while the prognostic specificity for psychosis prediction at 38 months 
was 47% (95%CI: 38 – 57%).22 These values indicate that CHR assessments have an 
outstanding ability to rule out psychosis risk and an only modest ability to rule in subsequent 
psychosis22.  
 
2.7 Sensitivity and Specificity in Receiver Operator Characteristic (ROC) Curves 
Sensitivity and specificity at different data points (e.g., sum scores) of continuous data can be 
plotted in the ROC curves. ROC curves plot (1−specificity) of a test on the x-axis against its 
sensitivity on the y-axis. The area under this curve (AUC) represents the overall accuracy of a 
test, with values of 0.9-1.0 (equal to 90-100%) considered outstanding, of 0.8-0.9 excellent 
and of 0.7-0.8 acceptable.23 The off-diagonal on the graph represents an AUC of 0.5, 
indicating only random discrimination, i.e., a test whose results are no better than tossing a 
coin. ROC curve for CHR assessment was reported as very good (AUC=0.90; 95%CI: 0.87-
0.93)22. 
 
2.8 Positive and Negative Predictive Values  
Accuracy measures that – other than sensitivity and specificity – are not considered 
independent of the risk of psychosis in the population to that a particular CHR patient belongs 
are the positive and negative predictive values (PPV, NPV)24.The PPV is the proportion of 
CHR+ subjects who actually have developed psychosis (T), whereas NPV is the proportion of 
CHR− subjects who have not developed psychosis (NT)25. The PPV of CHR assessment at 
different time points has been reported in an earlier meta-analysis, indicating a risk of 
psychosis onset among CHR+ subjects between 18% (95%CI: 12-25%) at 6 months, and 36% 
(95%CI: 24-35%) at more than 36 months5. Coming back to Example C, a CHR test with 
93.5% sensitivity and 40.3% specificity at 3 years, the corresponding risk of psychosis, PPV 
and NPV are: 
• Risk of psychosis the population assessed = (29 + 2) × 100 / 150 = 20.7% 
• PPV = CHR+T × 100 / (CHR+T + CHR+NT) = 29 × 100 / (29 + 71) = 29.0% 
• NPV = CHR−NT × 100 / (CHR−NT + CHR−T) = 48 × 100 / (48 + 2) = 96.0% 
 
Example D: Influence of the population’s risk of psychosis on PPV and NPV 
Let’s now assume we assess CHR in a different population of 973 subjects, 591 of whom 
will test CHR+ and 382 CHR−. Among the CHR+, 29 will develop psychosis (CHR+T) 
and 562 not (CHR+NT); among those CHR−, 2 would develop psychosis (CHR−T) and 
380 not (CHR−NT). Sensitivity and specificity would remain the same, sensitivity 93.5% 
and specificity 40.3%. However, the prevalence of psychosis risk in the population 
assessed would be lower, impacting in particular on the PPV: 
à Risk of psychosis in the population = (29 + 2) × 100 / 973 = 3.2% 
à PPV = 2900 / (29 + 562) = 4.9% 
à NPV = 38000 / (380 + 2) = 99.5% 
 
Although PPV and NPV may be used to estimate the individual probabilities of developing 
psychosis in CHR subjects26, their clinical usefulness is restricted to populations whose 
prevalence of disease is similar to the one from which they were estimated.26 Recent meta-
analyses indicated that the prevalence of psychosis in subjects undergoing CHR assessment is 
of 15%, with high heterogeneity (95% CI: 9%-24%) across individual sites.8 
 
2.9 Bayes’ Theorem and Predictive Ability of CHR Assessment 
Ultimately, the value of a test will depend upon its ability to alter a pre-test probability of a 
target condition into a post-test probability that will influence a clinical management 
decision25. Pre-test and post-test probability of psychosis in CHR subjects index an 
individual’s likelihood of the development of psychosis before and after the CHR assessment, 
respectively. To be clinically useful, the results of the CHR assessment should substantially 
change the pre-test probability of the individual patient to develop the disease, i.e., 
significantly in- or decrease his/her post-test probability27. These concepts are linked to Bayes’ 
theorem that describes the probability (P) of an event (e.g., transition to psychosis, T), based 
on conditions that might be related to the event (e.g., being CHR+). In case of early detection, 
Bayes' theorem can be stated mathematically as: 
 
P(T | CHR+) = P(CHR+ | T) × P(T) / P(CHR+)  
 
or in words: The conditional probability of development of psychosis given a positive CHR 
assessment, P(T | CHR+), is the product of the conditional probability of CHR+ given that 
psychosis develops, P(CHR+ | psychosis), and the probability of psychosis, P(T), divided by 
the probability of a positive CHR assessment, P(CHR+). 
 However, P(CHR+) and P(T) and, consequently, their related conditional probabilities are no 
fixed numbers but depend on sampling biases. For example, P(CHR+) and P(T) as well as 
P(T | CHR+) were higher in CHR samples recruited from mental health professionals than in 
those recruited from the community12. The same was true for predominately or exclusively 
adult samples compared to child and adolescent samples7. Thus, it is not only CHR criteria 
that determine the post-test probability of transition to psychosis but also the recruitment and 
selection of samples, which might create substantial enrichment in risk8. These concepts are 
illustrated in the probability modifying plot (Figure 2) which plots pre-test probability of 
developing psychosis before the CHR assessment on the x-axis against the post-test 
probability of developing psychosis after CHR assessment on the y-axis. The post-test 
probability in turns can be positive P(T | CHR+) or negative P(T | CHR-). The positive and 
negative posterior probability curves visually show that CHR assessment has an excellent 
ability to rule out psychosis, and a modest ability to rule in.  
 
*** FIGURE 2 ABOUT HERE *** 
 
2.10 Likelihood Ratios  
Several authors have suggested the use of positive and negative likelihood ratios (LR+, LR−) 
instead of sensitivity and specificity24 to better account for differences in the quality between 
the two and for pre-test probabilities. LRs combine the estimates of sensitivity and specificity 
and offer the advantage of existing guidelines for their quality assessment28. Thereby, LR+ (= 
Sensitivity / (1 – Specificity)) (table 1) gives the factor by that the pre-test probability 
increases given a positive test result, while LR− (= (1 – Sensitivity) / Specificity) gives the 
fraction to that the post-test probability decreases given a negative test result.  
As a rough guide, LR+ > 10 and LR− < 0.1 generate large and often diagnostically conclusive 
changes from pre- to post-test probability; LR+ of 5-10 and LR− of 0.1-0.2 produce moderate 
shifts in probability; LR+ of 2-5 and LR− of 0.2-0.5 result in small (but sometimes important) 
changes in probability, while LR+ < 2 and LR− > 0.5 change probability to a very small (and 
rarely important) degree24. A graphical presentation of LRs with the probability modifying 
plot (Figure 2) can improve the accuracy of estimated post-test disease probability in clinical 
practice. 17 
In a previous meta-analysis, we have shown that current CHR assessment has an excellent 
ability to rule out psychosis (LR− = 0.09), at an expense of their ability to rule in psychosis 
(LR+ = 1.82)22 and these LRs are reported in Figure 2. In fact, given a pre-test probability of 
15% in subjects referred to high risk services,8 the post-test probability of psychosis onset at 
38 months, given a CHR+ assessment is of 26% (95% CI: 23%-30%)22 and given a CHR- 
assessment is of 1.56% (95% CI: 0.7%-2.42%).22  
 
2.11 Assessing Psychosis-Risk in Clinical Practice: the Potentials and Pitfalls of Real-
Life Application 
While LRs thereby offer a good tool for the probabilistic assessment of individual risk, they 
were shown to be the least well understood accuracy measures by clinicians17, 29. Yet, 
probabilistic reasoning makes considerably demands on the clinician even beyond 
understanding of LRs, e.g. estimating an individual’s pre-test risk of psychosis onset based on 
available, often heterogeneous and fragmented information on population estimates, as 
roughly illustrated by Table 2. However, probabilistic reasoning in CHR has already been 
very useful in advising clinicians on the use of CHR assessment. As shown in table 2, 
probabilistic reasoning shows that CHR assessment should be restricted to populations 
seeking help at high risk services (case 3) only, to avoid small and negligible PPVs and NPVs 
(cases 1 and 2). Unfortunately, the pre-test probability of psychosis onset in different 
subsamples (e.g. migrants, substance users) of subjects seeking help at high-risk services is 
still not unknown. Thus, future research should overcome the limited pre-test probability 
data30 by providing CHR clinicians with reliable and simple, yet not over-simplistic 
information on pre-test probabilities in different samples seeking help at high risk services 
and LRs that is presented in a well-applicable, e.g., graphic form and with good guidelines for 
their use.  
 
*** TABLE 2 ABOUT HERE *** 
 
3. CONCLUSIONS 
The current reviews illustrated the basic concepts that are necessary for probabilistic 
reasoning in the CHR state. Understanding basic measures used for prognostic probabilistic 
reasoning is a prerequisite for successfully improving the prediction of psychosis in clinical 
practice27. Future refinement of these measures for CHR subjects may actually influence risk 
management, especially as regards initiating or withholding treatment.17 
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transition, given transition occurs by 2 years after presentation. The regression line (solid 
line) closely fitted the data points (R2 = 0.995; y = 133[1-e−0.06x]) and indicates that, among 
ultra-high risk individuals progressing to psychosis in the first 2 years, 25%will develop the 
disorder by 106 days and 50% by 240 days. 
Table 1. Measures of prognostic accuracy that can be calculated from a 2×2 table showing 
the cross-classification of a CHR assessment and subsequent gold standard assessment of 
psychosis. CHR, Clinical High Risk (UHR and/or BS); UHR, Ultra High Risk (including 
BLIPS/BIPS and/or APS and/or GRD); APS, Attenuated Psychosis Symptoms; GRD, Genetic 
Risk and Deterioration syndrome; BLIPS, Brief Limited Intermittent Psychotic Symptoms; 
BIPS, Brief Intermittent Psychotic Symptoms; BS, Basic Symptoms. Adapted from 8. 
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Pre-test probability (x axis 
in Figure 2) 
The probability of developing psychosis before the CHR assessment, also called the 
prevalence of the disease: (true positive+false negative)/(true positive+false 
postive+false negative+true negative). 
Sensitivity Proportion of subjects who will develop the psychosis who will have a positive CHR 
assessment result: true positive/(true positive+false negative}. 
Specificity The proportion of subjects without the development of psychosis who will have a 
negative CHR assessment result: true negative/(true negative+false positive). 
Positive Predictive Value 
(PPV) 
The proportion of subjects with a positive CHR assessment result who actually have 
developed psychosis: true positive/(true positive+false positive). 
Negative Predictive Value 
(NPV) 
The proportion of subjects with a negative CHR assessment result who do not have 
actually developed psychosis: true negative/(true negative+false negative). 
Accuracy The proportion of true results among the total number of CHR subjects assessed: 
(true positive+true negative)/(true positive+false positive+true negative+false 
negative). 
Positive Likelihood Ratio 
LR+ (legend to Figure 2) 
The probability of a CHR subject who develop psychosis testing positive at the CHR 
assessment divided by the probability of a person who does not develop the 
psychosis testing positive at the CHR assessment: sensitivity/(1-specificity) 
Negative Likelihood Ratio 
LR- (legend to Figure 2) 
The probability of a subject who develop psychosis testing negative at the CHR 
assessment divided by the probability of a subject who does not develop psychosis 
testing negative at the CHR assessment: (1-sensitivity)/specificity 
Post-test positive 
probability (red line in 
Figure 2) 
The individual probability of developing the disease given a positive prognostic test 
result: Pretest probability×Sensitivity/[(Pretest probability×Sensitivity)+(1−Pretest 
probability)×(1−Specificity)] 
Post-test negative 
probability (green line in 
Figure 2) 
The individual probability of developing the disease given a negative prognostic test 
result: (1−Pretest probability)×Specificity/[(1−Pretest 
probability)×Specificity)+Pretest probability×(1−Sensitivity)] 
Figure 2. Meta-analytical probability modifying plot, illustrating the relationship between 
pre-test probability of psychosis onset 38 months and post-test probability of psychosis risk at 
38 months based on CHR psychometric assessment in subjects seeking help at high risk 
services, computed as the likelihood of a positive (above diagonal line in red; LR+) or 
negative (below diagonal line in green, LR-) CHR assessment result over the 0-1 range of 
pre-test probability, adapted from 22. The vertical black line indicates the average pre-test 
probability of psychosis onset in subjects referred to high risk services (15% at 38 months8) 
which yields a 26% post-test probability of psychosis onset in CHR+ cases and a 1.56% post-
test probability of psychosis onset at 38 months in CHR- cases22. 
 
    
 
 
  
Table 2. Description of 3 hypothetical cases, from real world scenarios, illustrating the 
impact of different pre-test probabilities of psychosis onset related to potential sampling bias 
on estimated post-test probabilities of psychosis onset after CHR assessment, computed using 
the LRs indicated in Figure 2.22 
 case 1 case 2 case 3 
Population General Population Genetic high-risk 
population 
Mental health service 
users 
Setting School Relative’s self-
support group 
CHR service 
Gender a Male Female Male 
Age  21 years 19 years 20 years 
Ethnicity  Black Caribbean White White 
Family history of 
psychosis 
No Mother diagnosed 
with schizophrenia 
No 
Estimated 3-year risk 
of psychosis of 
population ≈ 3-year 
pre-test probability 
0.27% 
(Assuming an annual 
incidence of 
schizophrenia in the 
general population of 
Black Caribbean 
migrants of 0.091%31) 
4% 
(Assuming a 3 year 
risk of psychosis in 
offspring of mothers 
with schizophrenia as 
estimated from the 
Kaplan-Meier, Figure 2 
from32) 
15% 
(Assuming a 3-year 
risk for psychosis of 
15% in help-seeking 
samples referred to 
CHR services8) 
Assessment Interview 
(CHR assessment) 
Interview 
(CHR assessment) 
Interview 
(CHR assessment) 
3-year post-test 
probability in case of 
positive result (LR+ 
1.82) 22   
0.49% 7.05% 26% 
3-year post-test 
probability in case of 
negative result (LR- 
0.09) 22 
0.02% 0.38% 1.56% 
 
 
